Photo technique to support better wound care outcomes

Photo technique to support better wound care outcomes

July 31, 2018

A new technique for photographing wounds that could provide more information to support wound care in people with leg wounds is being investigated in a project funded by Trajan Scientific and Medical.

The Bolton Clarke Research Institute is working with RMIT to investigate hyperspectral imaging (HSI) as a faster way to let healthcare providers know when a leg wound is healing normally and when more treatment is needed to help heal the wound better.

The photographic technique uses up to 100 colour channels and reveals information that can normally only be discovered using pathology tests.

BCRI lead researcher Dr Rajna Ogrin said leg wounds happened more often in older people and could be painful, stopping people from going out and doing the things they need to do.

“They also may take a long time to heal and lead to complications like infections and needing to go to hospital,” she said.

“The most common type of leg wound is venous leg ulcers, which are wounds that don’t heal because veins don’t bring the blood back to the heart properly, and cause swelling in the legs and other problems.

“But a big problem in wounds is that it is hard to know which wounds won’t heal as expected, and so need more help to heal better.”

Previous research by RMIT has found that HSI can help better predict the healing of foot wounds in people with diabetes.

The new work will build on research already done and find out if there is extra information in HSI photos that will help predict how leg wounds will heal.

Trajan Scientific and Medical CEO Stephen Tomisich said, “On our journey developing technologies towards personalized measurement, we also look for opportunities to support others making a difference in the wider community.

“This program is aligned with our patient-centric ethos, using less-invasive techniques in order to produce meaningful data to assist in healthcare.”

“We are pleased to continue supporting Bolton Clarke, since first funding their Peer Educators for Skin Health Program in 2015, and now this collaboration with RMIT to improve wound care,” he said.

The research project, which will span 12 months, will include 80 Bolton Clarke clients with venous leg wounds in the Melbourne North region.

Clients will be followed up at 12 and 24 weeks.

Photo: Dr Judy Lowthian and Dr Rajna Ogrin, Bolton Clarke Research Institute

Example: Hyperspectral image used to show the blood oxygen level (red=high) of an ulcer with delayed healing.

Press release [PDF]

More information
Bolton Clarke

Media contact information 
Trajan Scientific and Medical
Tel: +44 (0) 1244 403 100

Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More